Comprehensive interrogation of the ADAR2 deaminase domain for engineering enhanced RNA editing activity and specificity

  1. Dhruva Katrekar
  2. Yichen Xiang
  3. Nathan Palmer
  4. Anushka Saha
  5. Dario Meluzzi
  6. Prashant Mali  Is a corresponding author
  1. University of California, San Diego, United States

Abstract

Adenosine deaminases acting on RNA (ADARs) can be repurposed to enable programmable RNA editing, however their enzymatic activity on adenosines flanked by a 5' guanosine is very low, thus limiting their utility as a transcriptome engineering toolset. To address this issue, we first performed a novel deep mutational scan of the ADAR2 deaminase domain, directly measuring the impact of every amino acid substitution across 261 residues, on RNA editing. This enabled us to create a domain wide mutagenesis map while also revealing a novel hyperactive variant with improved enzymatic activity at 5'-GAN-3' motifs. However, exogenous delivery of ADAR enzymes, especially hyperactive variants, leads to significant transcriptome wide off-targeting. To solve this problem, we engineered a split ADAR2 deaminase which resulted in 1000-fold more specific RNA editing as compared to full-length deaminase overexpression. We anticipate that this systematic engineering of the ADAR2 deaminase domain will enable broader utility of the ADAR toolset for RNA biotechnology and therapeutic applications.

Data availability

Sequencing data will be accessible via NCBI GEO under accession GSE158656. Source data has been made available with the submission.

The following data sets were generated
    1. Katrekar D
    (2022) ADAR Protein Engineering
    NCBI Gene Expression Omnibus, GSE158656.

Article and author information

Author details

  1. Dhruva Katrekar

    Bioengineering, University of California, San Diego, La Jolla, United States
    Competing interests
    Dhruva Katrekar, has filed a patent pertaining to the screening methodology, novel mutants and splitting of the ADAR2-DD (application number: 63/075,717). Is now an employee of Shape Therapeutics..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-8028-3244
  2. Yichen Xiang

    Department of Bioengineering, University of California, San Diego, La Jolla, United States
    Competing interests
    No competing interests declared.
  3. Nathan Palmer

    Division of Biological Sciences, University of California, San Diego, La Jolla, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-6347-9379
  4. Anushka Saha

    Department of Bioengineering, University of California, San Diego, La Jolla, United States
    Competing interests
    No competing interests declared.
  5. Dario Meluzzi

    Department of Bioengineering, University of California, San Diego, La Jolla, United States
    Competing interests
    No competing interests declared.
  6. Prashant Mali

    Department of Bioengineering, University of California, San Diego, La Jolla, United States
    For correspondence
    pmali@ucsd.edu
    Competing interests
    Prashant Mali, has filed a patent pertaining to the screening methodology, novel mutants and splitting of the ADAR2-DD (application number: 63/075,717). Is a scientific co-founder of Shape Therapeutics, Navega Therapeutics, Boundless Biosciences, and Engine Biosciences..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-3383-1287

Funding

National Human Genome Research Institute (R01HG009285)

  • Prashant Mali

National Cancer Institute (R01CA222826)

  • Prashant Mali

National Institute of General Medical Sciences (R01GM123313)

  • Prashant Mali

U.S. Department of Defense (PR210085)

  • Prashant Mali

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

© 2022, Katrekar et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 5,060
    views
  • 677
    downloads
  • 30
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Dhruva Katrekar
  2. Yichen Xiang
  3. Nathan Palmer
  4. Anushka Saha
  5. Dario Meluzzi
  6. Prashant Mali
(2022)
Comprehensive interrogation of the ADAR2 deaminase domain for engineering enhanced RNA editing activity and specificity
eLife 11:e75555.
https://doi.org/10.7554/eLife.75555

Share this article

https://doi.org/10.7554/eLife.75555

Further reading

    1. Biochemistry and Chemical Biology
    2. Structural Biology and Molecular Biophysics
    Angel D'Oliviera, Xuhang Dai ... Jeffrey S Mugridge
    Research Article

    The SARS-CoV-2 main protease (Mpro or Nsp5) is critical for production of viral proteins during infection and, like many viral proteases, also targets host proteins to subvert their cellular functions. Here, we show that the human tRNA methyltransferase TRMT1 is recognized and cleaved by SARS-CoV-2 Mpro. TRMT1 installs the N2,N2-dimethylguanosine (m2,2G) modification on mammalian tRNAs, which promotes cellular protein synthesis and redox homeostasis. We find that Mpro can cleave endogenous TRMT1 in human cell lysate, resulting in removal of the TRMT1 zinc finger domain. Evolutionary analysis shows the TRMT1 cleavage site is highly conserved in mammals, except in Muroidea, where TRMT1 is likely resistant to cleavage. TRMT1 proteolysis results in reduced tRNA binding and elimination of tRNA methyltransferase activity. We also determined the structure of an Mpro-TRMT1 peptide complex that shows how TRMT1 engages the Mpro active site in an uncommon substrate binding conformation. Finally, enzymology and molecular dynamics simulations indicate that kinetic discrimination occurs during a later step of Mpro-mediated proteolysis following substrate binding. Together, these data provide new insights into substrate recognition by SARS-CoV-2 Mpro that could help guide future antiviral therapeutic development and show how proteolysis of TRMT1 during SARS-CoV-2 infection impairs both TRMT1 tRNA binding and tRNA modification activity to disrupt host translation and potentially impact COVID-19 pathogenesis or phenotypes.

    1. Biochemistry and Chemical Biology
    2. Microbiology and Infectious Disease
    Qian Wang, Jinxin Liu ... Qian Liu
    Research Article

    Paramyxovirus membrane fusion requires an attachment protein for receptor binding and a fusion protein for membrane fusion triggering. Nipah virus (NiV) attachment protein (G) binds to ephrinB2 or -B3 receptors, and fusion protein (F) mediates membrane fusion. NiV-F is a class I fusion protein and is activated by endosomal cleavage. The crystal structure of a soluble GCN4-decorated NiV-F shows a hexamer-of-trimer assembly. Here, we used single-molecule localization microscopy to quantify the NiV-F distribution and organization on cell and virus-like particle membranes at a nanometer precision. We found that NiV-F on biological membranes forms distinctive clusters that are independent of endosomal cleavage or expression levels. The sequestration of NiV-F into dense clusters favors membrane fusion triggering. The nano-distribution and organization of NiV-F are susceptible to mutations at the hexamer-of-trimer interface, and the putative oligomerization motif on the transmembrane domain. We also show that NiV-F nanoclusters are maintained by NiV-F–AP-2 interactions and the clathrin coat assembly. We propose that the organization of NiV-F into nanoclusters facilitates membrane fusion triggering by a mixed population of NiV-F molecules with varied degrees of cleavage and opportunities for interacting with the NiV-G/receptor complex. These observations provide insights into the in situ organization and activation mechanisms of the NiV fusion machinery.